Neuroprotective Effect of the AMPA Receptor Antagonist LY-293558 in Focal Cerebral Ischemia in the Cat

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of Cerebral Blood Flow and Metabolism

• Publication date

  1994-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/jcbfm.1994.57PMID 8163588
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• (3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3 - carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist.

  1993cited by this paper
• Focal cerebral ischemia in the cat: pretreatment with a kappa-1 opioid receptor agonist, CI-977.

  1993cited by this paper
• Immediate or delayed mild hypothermia prevents focal cerebral infarction.

  1992cited by this paper
• The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat.

  1992cited by this paper
• Protection against ischemic hippocampal CAI damage in the rat with a new non‐NMDA antagonist, NBQX

  1992cited by this paper
• Cerebroprotective Effect of a Non–N‐Methyl‐D‐Aspartate Antagonist, GYKI 52466, After Focal Ischemia in the Rat

  1992influential reference
• The effect of the NMDA receptor antagonist MK-801 on cerebral blood flow and infarct volume in experimental focal stroke.

  1992cited by this paper
• The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model.

  1992cited by this paper
• Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adult rats.

  1991cited by this paper
• The neuroprotective action of dizocilpine (MK‐801) in the rat middle cerebral artery occlusion model of focal ischaemia

  1991cited by this paper
• Autoradiographic assessment of the effects of N-methyl-d-aspartate (NMDA) receptor antagonists in vivo

  1991cited by this paper
• Evaluation of a competitive NMDA antagonist (D‐CPPene) in feline focal cerebral ischemia

  1991cited by this paper
• Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia.

  1991cited by this paper
• 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia.

  1990cited by this paper
• Focal Cerebral Ischemia in the Cat: Pretreatment with a Competitive NMDA Receptor Antagonist, D-CPP-ene

  1990cited by this paper
• Rodent models of cerebral ischemia.

  1989cited by this paper
• Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia.

  1988cited by this paper
• Focal Cerebral Ischaemia in the Cat: Treatment with the Glutamate Antagonist MK-801 after Induction of Ischaemia

  1988cited by this paper
• Protective Effect of the Glutamate Antagonist, MK-801 in Focal Cerebral Ischemia in the Cat

  1988cited by this paper
• The nature, distribution and earliest stages of anoxic-ischaemic nerve cell damage in the rat brain as defined by the optical microscope.

  1968cited by this paper
• Topographischer Hirnatlas der Katze für experimental-physiologische Untersuchungen

  1963cited by this paper
• Journal of Cerebral Blood Flow and Metabolism Postischemic Blockade of Amp a but Not Nmda Receptors Mitigates Neuronal Damage in the Rat Brain following Transient Severe Cerebral Ischemia

  year unknowninfluential reference

• The role of AMPA and NMDA receptors in mitragynine effects on hippocampal synaptic plasticity.

  2022cites this paper
• Physiology and Pathology of Calcium Signaling in the Brain

  2012cites this paper
• Excitotoxic ATP and Glutamate Signalling during Central Nervous System Ischaemia

  2010cites this paper
• alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.

  2010cites this paper
• Kainate receptors: pharmacology, function and therapeutic potential.

  2009cites this paper
• Competitive AMPA receptor antagonists

  2007cites this paper
• Stroke: Mechanisms of Excitotoxicity and Approaches for Therapy

  2007cites this paper
• YM872: a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist.

  2006influential citation
• Neuroprotection and peptide toxins.

  2004cites this paper
• Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters.

  2004cites this paper
• Functional Characterization of YM928, a Novel Noncompetitive AMPA Receptor Antagonist

  2003cites this paper
• Molecular pathways in cerebral ischemia

  2003cites this paper
• Effect of AMPA receptor antagonist YM872 on cerebral hematoma size and neurological recovery in the intracerebral hemorrhage rat model.

  2003cites this paper
• Functional Characterization of YM928, a Novel Noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist

  2003cites this paper
• Grey Matter and White Matter Ischemic Damage is Reduced by the Competitive AMPA Receptor Antagonist, SPD 502

  2002cites this paper
• Traumatic brain injury: developmental differences in glutamate receptor response and the impact on treatment.

  2001cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2001cites this paper
• Characterization of Endogenous Amino Acid Efflux from Hippocampal Slices during Chemically-Induced Ischemia

  2001cites this paper
• Dopamine transporter and nitric oxide synthase in hypoxic-ischemic brain.

  2000cites this paper
• Phosphonate quinoxalinedione AMPA antagonists

  2000cites this paper
• Action of locally administered NMDA and AMPA/kainate receptor antagonists in spinal cord injury

  2000cites this paper
• LY377770, a novel iGlu5 kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischaemia.

  2000cites this paper
• Non-N-methyl-D-aspartate glutamate receptors mediate oxygen--glucose deprivation-induced oligodendroglial injury.

  2000cites this paper
• NMDA receptor antagonism, but not AMPA receptor antagonism attenuates induced ischaemic tolerance in the gerbil hippocampus.

  1999cites this paper
• Limiting Neurological Damage After Stroke

  1999cites this paper
• Disturbances of Calcium Homeostasis in Ischaemic Stroke

  1999cites this paper
• Evaluation of glycine site antagonists of the NMDA receptor in global cerebral ischaemia.

  1999cites this paper
• The neuroprotective effect of the novel AMPA receptor antagonist PD152247 (PNQX) in temporary focal ischemia in the rat.

  1999cites this paper
• Synergistic neuroprotective effects by combining an NMDA or AMPA receptor antagonist with nitric oxide synthase inhibitors in global cerebral ischaemia.

  1999cites this paper
• Ischemic cell death in brain neurons.

  1999cites this paper
• Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia.

  1998cites this paper
• YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats.

  1998cites this paper
• Neuroprotective effect of YM-39558 in focal cerebral ischemia in cats.

  1998cites this paper
• Neuroprotective effect of the novel glutamate AMPA receptor antagonist YM872 assessed with in vivo MR imaging of rat MCA occlusion.

  1998cites this paper
• Duration of neuroprotective treatment for ischemic stroke.

  1998cites this paper
• Penumbra and Reduces Brain Injury After Permanent Focal Ischemia in Rats YM 872 , a Highly Water-Soluble AMPA Receptor Antagonist , Preserves the Hemodynamic

  1998cites this paper
• New experimental and clinical data on the efficacy of pharmacological magnesium infusions in cerebral infarcts.

  1998cites this paper
• YM872, a Novel Selective α-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Antagonist, Reduces Brain Damage after Permanent Focal Cerebral Ischemia in Cats

  1998cites this paper
• Highly Water-Soluble AMPA Receptor Antagonist , Preserves the Hemodynamic Penumbra and Reduces Brain Injury After Permanent Focal Ischemia in Rats

  1998cites this paper
• In‐vitro Characterization of YM872, a Selective, Potent and Highly Water‐soluble α‐Amino‐3‐hydroxy‐5‐methylisoxazole‐4‐propionate Receptor Antagonist

  1998cites this paper
• Neuropharmacology of AMPA and kainate receptors.

  1998cites this paper
• Neuroprotective effect of sumatriptan, a 5-HT(1D) receptor agonist, in focal cerebral ischemia of rat brain.

  1998cites this paper
• Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia.

  1998cites this paper
• Neuroprotective effects depend on the model of focal ischemia following middle cerebral artery occlusion.

  1998cites this paper
• The putative AMPA receptor antagonist, LY326325, produces anxiolytic-like effects without altering locomotor activity in rats.

  1998cites this paper
• Pharmacological Advances in Cerebrovascular Protection

  1998cites this paper
• Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo.

  1997cites this paper
• Neuroprotective effect of a novel AMPA receptor antagonist, YM90K, in rat focal cerebral ischaemia.

  1997cites this paper
• [Post-traumatic intracranial hypertension and biochemical disorders: cases and consequences].

  1997cites this paper
• Neuroprotective Drug Therapy: A Medical and Pharmacological Treatment for Tinnitus Control.

  1997cites this paper
• AMPA receptor antagonist, YM90K, reduces infarct volume in thrombotic distal middle cerebral artery occlusion in spontaneously hypertensive rats.

  1997cites this paper
• Pharmacology of AMPA antagonists and their role in neuroprotection.

  1997cites this paper
• Hypertension intracrânienne post-traumatique et désordres biochimiques:causes et conséquences

  1997cites this paper
• Experimental neuronal protection in cerebral ischaemia Part II: Potential neuroprotective drugs.

  1997cites this paper
• Trends and Future Developments in the Pharmacological Treatment of Acute Ischaemic Stroke

  1997cites this paper
• Effect of CP101,606, a novel NR2B subunit antagonist of the N-methyl-D-aspartate receptor, on the volume of ischemic brain damage off cytotoxic brain edema after middle cerebral artery occlusion in the feline brain.

  1997cites this paper
• Voltage‐Activated Calcium Channels: Targets of Antiepileptic Drug Therapy?

  1997cites this paper
• Therapeutic Potential of AMPA Receptor Ligands in Neurological Disorders

  1996cites this paper
• Neuroprotective drug development in stroke: blood pressure and its impact.

  1996cites this paper
• Neuroprotective Effect of YM90K, a Novel AMPA/Kainate Receptor Antagonist, in Focal Cerebral Ischemia in Cats

  1996cites this paper
• Inhibitory effect of MS-153 on elevated brain glutamate level induced by rat middle cerebral artery occlusion.

  1996cites this paper
• Excitotoxic damage in neurotrauma: fact or fiction

  1996cites this paper
• Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 1. Effects of stereochemistry, chain length, and chain substitution.

  1996cites this paper
• Endothelin Receptor Antagonist Increases Cerebral Perfusion and Reduces Ischaemic Damage in Feline Focal Cerebral Ischaemia

  1996cites this paper
• The AMPA Antagonist LY293558 Improves Functional Neurological Outcome following Reversible Spinal Cord Ischemia in Rabbits

  1996cites this paper
• Excitatory amino acid antagonists

  1996cites this paper
• Neuroprotective effects of 7-nitroindazole in the gerbil model of global cerebral ischaemia.

  1996cites this paper
• Stereoselective effects-of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies.

  1996cites this paper
• Characterization of YM90K, a selective and potent antagonist of AMPA receptors, in rat cortical mRNA-injected Xenopus oocytes.

  1996cites this paper
• Neurodegenerative disorders: clues from glutamate and energy metabolism.

  1996cites this paper
• Structure-activity studies of 6-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 2. Effects of distal acid bioisosteric substitution, absolute stereochemical preferences, and in vivo activity.

  1996cites this paper
• The effects of ifenprodil and eliprodil on voltage-dependent Ca2+ channels and in gerbil global cerebral ischaemia.

  1996cites this paper
• Mechanisms of glutamate and aspartate release in the ischemic rat cerebral cortex.

  1996cites this paper
• Excitotoxicity and neurodegenerative diseases.

  1995cites this paper
• Effects of decahydroisoquinoline-3-carboxylic acid monohydrate, a novel AMPA receptor antagonist, on glutamate-induced CA2+ responses and neurotoxicity in rat cortical and cerebellar granule neurons.

  1995cites this paper
• AMPA receptor antagonism attenuates MK-801-induced hypermetabolism in the posterior cingulate cortex.

  1995cites this paper
• Monthlyupdate - Central & peripheral nervous systems: Pharmacotherapeutic potential for compounds acting at NMDA receptors: Update 1995

  1995cites this paper
• Clinical Potential for the Use of Neuroprotective Agents. A Brief Overview

  1995cites this paper
• [Pharmacologic brain protection: specific agents].

  1995cites this paper
• Options for cerebral protection after penetrating head injury.

  1995cites this paper
• Possible Mechanisms of Pharmacological Neuronal Protection

  1995cites this paper
• Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex.

  1995cites this paper
• In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid.

  1995cites this paper
• The role of glutamic acid in the pathogenesis of stroke and the development of neuroprotective drugs.

  1995cites this paper
• AMPA antagonist LY293558 does not affect the severity of hypoxic-ischemic injury in newborn pigs.

  1995cites this paper
• Clinical experience with excitatory amino acid antagonist drugs.

  1995cites this paper
• Neuroprotective effects of 619C89, a use-dependent sodium channel blocker, in rat traumatic brain injury.

  1995cites this paper
• Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity.

  1995cites this paper
• Protection cérébrale médicamenteuse : agents spécifiques

  1995cites this paper
• Cytoprotective therapies in stroke.

  1995cites this paper
• The sigma receptor ligand JO 1784 (igmesine hydrochloride) is neuroprotective in the gerbil model of global cerebral ischaemia.

  1995cites this paper
• Brain protection during neurosurgery: an update from the anaesthetist's perspective.

  1995cites this paper
• Research report Effec(of eliprodil, an NMDA receptor antagonist acting at the polyamine modulatory site, on local cerebral glucose use in the rat brain

  1994cites this paper
• AMPA receptor antagonists and local cerebral glucose utilization in the rat.

  1994cites this paper
• The pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia.

  1994cites this paper
• Effect of eliprodil, an NMDA receptor antagonist acting at the polyamine modulatory site, on local cerebral glucose use in the rat in the rat brain.

  1994cites this paper
• The neuroprotective effects of the decahydroisoquinoline, LY 215490; a novel AMPA antagonist in focal ischaemia.

  1994cites this paper